for malignant lymphoma and responded to ribavirin
Seiya Hashimoto1) , Hirofumi Fukuda1) *, Kohei Takeda1),
Keiichi Uchida1), Fumiaki Sanuki2), Takashi Akiyama2), Eisei Kondo1), Hideho Wada1)
Department of Hematology, Kawasaki Medical School, Kurashiki, Japan
Department of Pathology, Kawasaki Medical School, Kurashiki, Japan
*Corresponding author E-mail address: fukuda7@med.kawasaki-m.ac.jp (H. Fukuda).